ReviewJournal of nanobiotechnology2025
In situ radiochemical doping of functionalized inorganic nanoplatforms for theranostic applications: a paradigm shift in nanooncology.
Review in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Upconversion nanoplatform unlocks the theranostic potential of Lu-177 radiotherapy via c-MET axis targeting in head and neck squamous cell carcinoma.Materials today. Bio · 2026Article
- Linking In Vivo Imaging to Therapeutic Outcome withInternational journal of molecular sciences · 2026Review
- Engineering intrinsically radiolabeled nanoparticles for imaging and therapy: a decade of design strategies and insights.RSC advances · 2026Review
- Radiolabeled exosomes for theranostics: Personalized tailored therapy through imaging.World journal of radiology · 2026Review
- A single-step radiolabeling strategy for PET, SPECT, and therapeutic radionuclides using nanoparticles as a universal chelator.Npj imaging · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In situ radiochemical doping presents a transformative approach for synthesizing radiolabeled inorganic nanoparticles (NPs) for cancer theranostics. Traditional radiolabeling techniques rely on bifunctional chelators, which often require harsh reaction conditions that can degrade the physicochemical properties of NPs. Additionally, the enzymatic dissociation of radiometals can potentially induce in vivo toxicity. In contrast, in situ doping directly incorporates radiometals into the NP crystal lattice, significantly enhancing both radiolabeling yield and radiochemical stability. This method preserves the pharmacokinetic profiles of the radiolabeled NPs, improving their theranostic efficacy. This review provides an up-to-date overview of the progress made in the development of radiolabeled inorganic nanoplatforms through in situ doping, with a focus on their stability, physicochemical characteristics, and applications in cancer theranostics. Our findings highlight the advantages in situ doping as a more efficient and stable alternative to conventional radiolabeling methods, offering substantial potential for the development of more effective cancer theranostic agents.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.